Leadership for HIV/AIDS Clinical Trials Networks; HIV Vaccine Trials Network

艾滋病毒/艾滋病临床试验网络的领导；

• 批准号: 7068349
• 负责人: STEVEN G. SELF
• 金额: $ 986.2万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-06-29 至 2013-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7068349
• 关键词: AIDS; AIDS vaccines; clinical research; clinical trials; disease outbreaks; leadership; prevention

EXCEED THE SPACE PROVIDED. Project Summary: This proposal describes the organization of a comprehesive, multidisciplinary, international HIV Vaccine Trials Network (HVTN). Components of the HVTN include a Leadership Coordinating and Operations Center (L. Corey, PI; J.N. Wasserheit, Director), a Statistical and Data Management Center (S.G. Self, PI),and a Network Laboratory Program (M.J. McElrath, PI). The HVTN's mission is to provide an objective and transparent platform to evaluate candidate HIV vaccines for the prevention of HIV infection in adult and adolescent populations globally. To achieve this, the HVTN will perform safety, immunogenicity, and efficacy trials of candidate HIV vaccines and adjuvants; conduct head- to-head comparisons of candidate vaccines; develop laboratory and statistical approaches to define potential correlates of protection; design trials to estimate the effects of vaccines that reduce HIV viral set point on HIV transmission; conduct trials of candidate vaccines in special populations, such as adolescents and intravenous drug users; develop a community education program to enhance the enrollment and retention of populations at high risk for HIV acquisition; develop standardized risk reduction counseling methods; and collaborate with other NIH networks, federal agencies and non-governmental research organizations to advance the highest quality HIV vaccine research,with optimal efficiency and cost effectiveness. Relevance: The progression of the HIV epidemic, as well as the international, political, and economic toll, make a compelling case for an effective preventive HIV vaccine. While other prevention strategies offer important advances in slowing the rate of spread of HIV, the high incidence of asymptomatic persistently infected HIV-infected persons requires the development of an effective vaccine. In order to reduce the spread of this global pandemic a robust integrated laboratory and clinical trials network is a necessary driver of the HIV vaccine field.

超过空间 假如。 项目摘要：该提案描述了一个理解的，多学科的组织 国际艾滋病毒疫苗试验网络（HVTN）。 HVTN的组成部分包括领导 协调与运营中心（L. Corey，Pi； J.N. Wasserheit，董事），统计和数据 管理中心（S.G. Self，PI）和网络实验室计划（M.J. McElrath，PI）。 HVTN的 任务是提供一个客观透明的平台，以评估候选艾滋病毒疫苗的疫苗 全球成人和青少年种群预防HIV感染。为了实现这一目标，HVTN将 对候选HIV疫苗和佐剂进行安全性，免疫原性和功效试验；进行头 - 候选疫苗的待办事项比较；开发实验室和统计方法来定义潜力 保护相关；设计试验以估计降低HIV病毒设定点对HIV的疫苗的影响 传播;在特殊人群中进行候选疫苗的试验，例如青少年和 静脉吸毒者；制定社区教育计划，以增强入学和保留 艾滋病毒收购风险高的人群；开发标准化的降低风险咨询方法；和 与其他NIH网络，联邦机构和非政府研究组织合作 提高最高质量的HIV疫苗研究，具有最佳的效率和成本效益。 相关性：艾滋病毒流行的发展以及国际，政治和经济损失， 为有效的预防性HIV疫苗提供令人信服的案例。而其他预防策略提供 降低艾滋病毒传播率的重要进展，无症状的高发生率 受感染的HIV感染者需要开发有效的疫苗。为了减少 这个全球大流行的传播是一个强大的集成实验室和临床试验网络是必要的驱动因素 艾滋病毒疫苗场。